Meeting slides
Interactive presentation

Scientific Insights Into Incretin Signaling and Type 2 Diabetes

Vivian Fonseca, MD, FRCP
Suggested Readings

Standards of medical care in diabetes—2014.

American Diabetes Association. Diabetes Care. 2014;37(suppl 1):S14-S18.

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.

AACE comprehensive diabetes management algorithm 2013.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2013;19:327-336.

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Diabetes Care. 2011;34 (suppl 2):S251-S257.

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Horton ES, Silberman C, Davis KL, Berria R. Diabetes Care. 2010;33:1759-1765.

GLP-1 receptor agonists: effects on cardiovascular risk reduction.

Lorber D. Cardiovasc Ther. 2013;31:238-249.

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.

Macconell L, Pencek R, Li Y, Maggs D, Porter L. Diabetes Metab Syndr Obes. 2013;6:31-41.

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.

Stolar MW, Grimm M, Chen S. Diabetes Metab Syndr Obes. 2013;6:435-444.

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.

Tschope D, Hanefeld M, Meier JJ, et al. Cardiovasc Diabetol. 2013;12:62.

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, et al. Diabetes Obes Metab. 2013;15:737-749.